NCT00577642 · ADVERSE EVENTS

Adverse events

Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates · Source last updated 2017-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: 6 months
Other-event reporting threshold: 5%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Single Arm Study This was a nonintervention biomarker study after a single dose of Zoledronic acid.	0 / 29	0 / 29	Not reported / Not reported

Group identifiers: EG000: Single Arm Study

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

description
This was a nonintervention biomarker study after a single dose of Zoledronic acid.
id
EG000
other Num Affected
0
other Num At Risk
29
serious Num Affected
0
serious Num At Risk
29
title
Single Arm Study

frequency Threshold

time Frame

6 months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice